Incidence and economics of transvenous ICD lead complications: Implications for tricuspid valve function and interventions.

Autor: Mason PK; Department of Medicine, University of Virginia, Charlottesville, Virginia, USA., Schloss EJ; Lindner Research Center, The Christ Hospital, Cincinnati, Ohio, USA., Holbrook R; Medtronic, Inc., Mounds View, Minnesota, USA., Chiddarwar T; Medtronic, Inc., Mounds View, Minnesota, USA., Zhou J; Medtronic, Inc., Mounds View, Minnesota, USA., Crossley GH; Heart and Vascular Institute, Vanderbilt University, Nashville, Tennessee, USA.
Jazyk: angličtina
Zdroj: Journal of cardiovascular electrophysiology [J Cardiovasc Electrophysiol] 2024 Oct; Vol. 35 (10), pp. 2056-2057. Date of Electronic Publication: 2024 Jul 30.
DOI: 10.1111/jce.16385
Abstrakt: Background: Implantable cardioverter-defibrillators are used globally and are reliable, but complications related to transvenous leads remain a concern. Evidence related to the incidence and costs of those complications is heterogeneous with respect to scope and healthcare system. This analysis aims to create estimates of the incidence and costs of tricuspid valve (TV) complications, lead failures, and lead extractions from a single large real-world data set.
Methods and Results: This retrospective longitudinal cohort study used the deidentified Medicare Fee for Service administrative claims database. A total of 116 036 patients with de novo transvenous ICD implant were analyzed. Mean hospital costs were $26 903 for tricuspid valve complications, $20 851 for lead failures, and $22 278 for lead extractions.
Conclusions: Transvenous ICD lead complications incur significant costs to patients, hospitals, and payers when they occur. Advancements in lead technology that reduce these complications could bring significant clinical and economic value.
(© 2024 The Author(s). Journal of Cardiovascular Electrophysiology published by Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: